HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer, His & Avi, Human

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer, His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
Z06608
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer[Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide]
Accession # NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAGGVGK		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
Synonyms MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.